BIOXCEL THERAPEUTICS ($BTAI) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$2.45 per share, missing estimates of -$1.89 by $0.56. The company also reported revenue of $120,000, missing estimates of $255,000 by $-135,000.
You can see Quiver Quantitative's $BTAI stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOXCEL THERAPEUTICS Hedge Fund Activity
We have seen 1 institutional investors add shares of BIOXCEL THERAPEUTICS stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 4,315,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,759,450
- UBS GROUP AG removed 1,276,893 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,592,092
- VANGUARD GROUP INC removed 1,187,466 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,410,555
- BLACKROCK, INC. removed 380,608 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $772,634
- GEODE CAPITAL MANAGEMENT, LLC removed 311,965 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $633,288
- WELLS FARGO & COMPANY/MN removed 199,010 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $403,990
- MILLENNIUM MANAGEMENT LLC removed 104,972 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $213,093
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIOXCEL THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $BTAI in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- LUCID CAPITAL MARKETS issued a "Buy" rating on 07/15/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/23/2025
- Rodman & Renshaw issued a "Buy" rating on 03/19/2025
To track analyst ratings and price targets for BIOXCEL THERAPEUTICS, check out Quiver Quantitative's $BTAI forecast page.
BIOXCEL THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $BTAI recently. We have seen 3 analysts offer price targets for $BTAI in the last 6 months, with a median target of $65.0.
Here are some recent targets:
- Elemer Piros from LUCID CAPITAL MARKETS set a target price of $66.0 on 07/15/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $8.0 on 06/23/2025
- Elemer Piros from Rodman & Renshaw set a target price of $65.0 on 03/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
